General Comments / Chat, page-12820

@RaceOncology

Hey Dr T,

Re: Marketing of Bisantrene and Race

Some one posted on another thread about marketing...
I am curious to understand where Race is at with the marketing of Bis and Race Oncology.

Given the limited human and finance resources at Race, are you able to please share the non market sensitive information on the following?

• Have you built , or are you building , or planning to build , a Marketing Plan with materials ready to go?

• Is there a typical marketing playbook for Biotechs developing a drug, or is it a more rudimentary process and left to market announcements and presentations to investor groups?

• Is there a particular event upon which the marketing plan will be executed?

i.e. evidence of CP, or release of the MOA, or regulatory approval

• Is there much point in the general media and population knowing about Bis and Race?

Perhaps patient pressure on Doctors and Oncologists and Govts for the very best standard of care...

• Is marketing best directed at those that decide the treatment, which means after regulatory approval?

I read this in the book "The Antidote"

Perhaps for now, you might just advise that all that matters to Race is the SP is well above $2, so Piggy Options are easily converted, and Race has the funds required for the programs until 28/29.

Thanks to you, and the team for your time and amazing efforts thus far.

I hope you get a chance to relax this weekend.

Cheers